News
VIVS
0.1503
-1.12%
-0.0017
Weekly Report: what happened at VIVS last week (1019-1023)?
Weekly Report · 1d ago
VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
Benzinga · 6d ago
Weekly Report: what happened at VIVS last week (1012-1016)?
Weekly Report · 10/19 09:13
VivoSim Labs Optimizes Headquarters Lease and Space Usage
TipRanks · 10/16 20:33
Weekly Report: what happened at VIVS last week (1005-1009)?
Weekly Report · 10/12 09:14
VivoSim Labs Highlights FDA Pathway For Human-Based Safety Testing;Stock Up
NASDAQ · 10/07 12:36
VivoSim celebrates updated FDA regulations in non-animal testing methods
TipRanks · 10/07 12:10
Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use
Benzinga · 10/07 12:06
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
Barchart · 10/07 07:05
VivoSim Labs Shareholders Approve Governance and Capital Changes
TipRanks · 10/06 20:40
Weekly Report: what happened at VIVS last week (0928-1002)?
Weekly Report · 10/05 09:14
Weekly Report: what happened at VIVS last week (0921-0925)?
Weekly Report · 09/28 09:13
Weekly Report: what happened at VIVS last week (0914-0918)?
Weekly Report · 09/21 09:13
VivoSim Labs Presents New NAMkind Data At EUROTOX 2026
NASDAQ · 09/16 12:32
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
Barchart · 09/16 07:05
Weekly Report: what happened at VIVS last week (0907-0911)?
Weekly Report · 09/14 09:14
Weekly Report: what happened at VIVS last week (0831-0904)?
Weekly Report · 09/07 09:13
VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities
Benzinga · 09/01 12:09
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
Barchart · 09/01 07:05
Weekly Report: what happened at VIVS last week (0824-0828)?
Weekly Report · 08/31 09:14
More
Webull provides a variety of real-time VIVS stock news. You can receive the latest news about VivoSim Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIVS
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.